Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 180

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 180
---
 equal quarterly installments of 237,500 options, beginning with the quarter ended March 31, 2024. The options
are exercisable within eight years from grant date.

The agreements contain customary confidentiality
obligations which are not limited by the term of the agreement.

<div align='center'>111</div>

Compensation of Directors

The following table sets forth the components
of compensation for each non-employee director that served as a director during the year ended December 31, 2024:

Year Ended December 31, 2024

| Name               |     | Fees earned 
 or paid in  
 cash        
 $           |        |     | Stock  
 awards 
 $      |    |     | Option     
 awards (1) 
 $          |         |     | Non-Equity     
 Incentive Plan 
 Compensation   
 $              |    |     | Non-Qualified 
 deferred      
 compensation  
 $             |    |     | all other    
 compensation 
 $            |        |     | Total 
 $     |         |
| Bernard Bertal (2) |     |             | 10,000 |     |        | -- |     |            | 172,000 |     |                | -- |     |               | -- |     |              | 57,000 |     |       | 239,000 |
| Mordechai Munk     |     |             | 10,000 |     |        | -- |     |            |      -- |     |                | -- |     |               | -- |     |              |     -- |     |       |  10,000 |
| Moti Jacobson (3)  |     |             | 10,000 |     |        | -- |     |            |      -- |     |                | -- |     |               | -- |     |              |     -- |     |       |  10,000 |
| Eyal Flom (4)      |     |             | 10,000 |     |        | -- |     |            |      -- |     |                | -- |     |               | -- |     |              |     -- |     |       |  10,000 |

| (1) | In accordance with SEC rules, the amounts in this column reflect the fair value on the grant date of the option awards granted to the named executive, calculated in accordance with ASC Topic 718. Stock options were valued using the Black-Scholes model